PKI-402 I-1 Smiles: COC(=O)NCCO[C@H]([C@@H]1CCCN(C1)C(=O)NC[C@H](C[C@H]1CCCOC1)NC)C1=CC(Cl)=CC=C1

Smiles: COC(=O)NCCO[C@H]([C@@H]1CCCN(C1)C(=O)NC[C@H](C[C@H]1CCCOC1)NC)C1=CC(Cl)=CC=C1

InChi: InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8

InChiKey: XMOCLSLCDHWDHP-IUODEOHRSA-N

Pomalidomide 4-alkylC7-acid

Smiles: OC(=O)CCNC(=O)C1C=CC(=CC=1)/N=N/C1=CC(=C(O)C=C1)C(O)=O

PKI-402 I-1 Smiles: COC(=O)NCCO[C@H]([C@@H]1CCCN(C1)C(=O)NC[C@H](C[C@H]1CCCOC1)NC)C1=CC(Cl)=CC=C1PKI 402 is a selective, reversible, ATP competitive, equipotent inhibitor of class I phosphatidylinositol 3 kinases (PI3K), including PI3K alpha mutants, and mammalian target of rapamycin (mTOR; IC(50) versus PI3K alpha = 2 nmol L). PKI 402 inhibited growth of human tumor cell lines derived from breast, brain (glioma), pancreas, and non small cell lung cancer tissue and suppressed phosphorylation of PI3K and mTOR effector proteins (e. g., Akt at T308)